Page 99 - Read Online
P. 99

before performing study. If ethics approval for certain survey study is not required, authors must include a statement to
           explain this clearly in the manuscript.
           3.1.6 Trial Registration
           AND requires all authors to register all relevant clinical trials that are reported in manuscripts submitted. AND follows the
           World Health Organization (WHO)’s definition of clinical trials: “A clinical trial is any research study that prospectively
           assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on
           health outcomes. Interventions include but are not restricted to drugs, cells, other biological products, surgical procedures,
           radiologic procedures, devices, behavioral treatments, process-of-care changes, preventive care, etc.”.
           In line with International Committee of Medical Journal Editors (ICMJE) recommendation, AND requires the registration
           of clinical trials in a public trial registry at or before the time of first patient enrollment. AND accepts publicly accessible
           registration in any registry that is a primary register of the WHO International Clinical Trials Registry Platform or in
           ClinicalTrials.gov. The trial registration number should be listed at the end of the Abstract section.
           Secondary data analyses of primary (parent) clinical trials should not be registered as a new clinical trial, but rather
           reference the trial registration number of the primary trial.
           Editors of AND will consider carefully whether studies failed to register or had an incomplete trial registration. Because
           of the importance of prospective trial registration, if there is an exception to this policy, trials must be registered and the
           authors should indicate in the publication when registration was completed and why it was delayed. Editors will publish
           a statement indicating why an exception was allowed. Please note such exceptions should be rare, and authors failing to
           prospectively register a trial risk its inadmissibility to AND.
           Authors who are not sure whether they need trial registration may refer to ICMJE FAQs for further information.
           3.2 Research Involving Animals
           Experimental  research  on  animals  should  be  approved  by  an  appropriate  ethics  committee  and  must  comply  with
           institutional, national, or international guidelines.  AND  encourages  authors  to  comply  with  the  AALAS  Guidelines,
           the ARRIVE Guidelines, and or the ICLAS Guidelines, and obtain prior approval from the relevant ethics committee.
           Manuscripts must include a statement indicating that the study has been approved by the relevant ethical committee and the
           whole research process complies with ethical guidelines. If a study is granted an exemption from requiring ethics approval,
           the name of the ethics committee granting the exemption and the reason(s) for the exemption should be detailed. Editors
           will take account of animal welfare issues and reserve the right to reject a manuscript, especially if the research involves
           protocols that are inconsistent with commonly accepted norms of animal research.
           3.3 Research Involving Cell Lines
           Authors must describe what cell lines are used and their origin so that the research can be reproduced. For established cell
           lines, the provenance should be stated and references must also be given to either a published paper or to a commercial
           source. For de novo cell lines derived from human tissue, appropriate approval from an institutional review board or
           equivalent ethical committee, and consent from the donor or next of kin, should be obtained. Such statements should be
           listed on the Declaration section of Ethical Approval and Consent to Participate in the manuscript.
           Further information is available from the International Cell Line Authentication Committee (ICLAC). AND recommends
           that authors check the NCBI database for misidentification and contamination of human cell lines.

           3.4 Research Involving Plants
           Experimental  research  on  plants  (either  cultivated  or  wild),  including  collection  of  plant  material,  must  comply  with
           institutional, national, or international guidelines. Field studies should be conducted in accordance with local legislation,
           and the manuscript should include a statement specifying the appropriate permissions and or licenses. AND recommends
           that authors comply with the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention
           on the Trade in Endangered Species of Wild Fauna and Flora.
           For each submitted manuscript, supporting genetic information and origin must be provided for plants that were utilized. For
           research manuscripts involving rare and non-model plants (other than, e.g., Arabidopsis thaliana, Nicotiana benthamiana,
           Oriza sativa, or many other typical model plants), voucher specimens must be deposited in a public herbarium or other
           public collections providing access to deposited materials.
           3.5 Publication Ethics Statement
           OAE is a member of the Committee on Publication Ethics (COPE). We fully adhere to its Code of Conduct and to its Best
           Practice Guidelines.
           The Editors of AND enforce a rigorous peer-review process together with strict ethical policies and standards to guarantee to
           add high-quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification,
           image manipulation, inappropriate authorship credit, and the like, do arise. The Editors of AND take such publishing ethics
           issues very seriously and are trained to proceed in such cases with zero tolerance policy.
           Authors wishing to publish their papers in AND must abide to the following:
           The author(s) must disclose any possibility of a conflict of interest in the paper prior to submission.
           The authors should declare that there is no academic misconduct in their manuscript in the cover letter.
           Authors should accurately present their research findings and include an objective discussion of the significance of their
           findings.
           Data and methods used in the research need to be presented in sufficient detail in the manuscript so that other researchers


                  Ageing and Neurodegenerative Diseases                                                   XII
   94   95   96   97   98   99   100   101   102